|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation | |||||
| Depreciation and amortization | |||||
| Amortization of debt discounts | |||||
| CSI Convertible Notes | |||||
| Total amortization of debt discounts | |||||
| Amortization of debt discounts and paid-in-kind interest | |||||
| Change in fair value of 10% convertible notes | |||||
| Fair value remeasurement of crypto assets | |||||
| Loss on sale of crypto assets | |||||
| Fair value of equity warrants in interest expense | |||||
| NYIAX | |||||
| Loss reserve | |||||
| Change in fair value of warrant liability | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Related party receivable | |||||
| Unbilled accounts receivable | |||||
| Inventories | |||||
| Crypto assets | |||||
| Prepaid expenses and other current assets | |||||
| Prepaid software | |||||
| Other assets | |||||
| Accounts payable | |||||
| Due to related party | |||||
| Accrued liabilities | |||||
| Other liabilities | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Issuance of note receivable | |||||
| Deposit for business combination | |||||
| Payments for business acquisition | |||||
| Purchases of property and equipment | |||||
| Purchases of intangible assets | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Proceeds from issuance of notes payable | |||||
| Proceeds from issuance of common stock, net of offering costs | |||||
| Proceeds from issuance of common stock in connection with warrant exercise | |||||
| Proceeds from issuance of common stock, prefunded warrants and warrants, net of issuance costs | |||||
| Proceeds from issuance of short-term loan, net of issuance costs | |||||
| Proceeds from issuance of Series B preferred stock, net of issuance costs | |||||
| Proceeds from exercise of warrants | |||||
| Repurchase of Series B preferred stock | |||||
| Repayment of finance lease | |||||
| Repayment of convertible note payable | |||||
| Repurchase of short term loan | |||||
| Issuance of securities in Big Lake transaction | |||||
| Repayment of convertible note payable, related party | |||||
| Payments on short-term debt | |||||
| Other equity issuances | |||||
| Repurchase of common stock warrants | |||||
| Net cash provided by financing activities | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents as of beginning of period | |||||
| Cash and cash equivalents as of end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for interest | |||||
| Cash paid for income taxes | |||||
| Noncash Investing and Financing Activities: | |||||
| Deemed dividend on conversion of convertible preferred for common stock | |||||
| Convertible preferred stock dividend | |||||
| Reclassification of liability warrants to equity warrants | |||||
| Issuance of warrant liability in connection with financing | |||||
| Deemed dividend on conversion of Series B preferred stock and repurchase of Series B preferred stock | |||||
| Derecognition of Series B preferred stock liability warrants | |||||
| Issuance of stock-based compensation to vendors | |||||
| Warrant exercise in connection with loan settlement | |||||
| Issuance of common stock in connection with Series B preferred stock | |||||
| Unpaid financings issuance costs | |||||
| Issuance of common stock and convertible note payable in connection with the acquisition of intangible assets | |||||
| Unpaid intangible assets acquisition costs | |||||
| Cashless exercise of warrants | |||||
| Reclassification of equity warrants to liability warrants | |||||
| Cumulative effect of adoption of ASU 2020-06 | |||||
| Issuance of common stock in connection with conversion of Series B preferred stock | |||||
| DV Convertible Note | |||||
| CSI Convertible Notes | |||||
| 10% Note conversions | |||||
| Total issuance of common stock in connection with conversion of Series B preferred stock | |||||
| Deemed dividend from accretion, amortization, and conversion of Series B preferred stock discounts | |||||
| Issuance of warrants in connection with February 2023 offering | |||||
| Issuance of common stock in connection with convertible promissory note | |||||
| Record Right-of-Use Assets obtained in exchange for modified operating lease liabilities | |||||
| Deferred offering costs reclassed from prepaid expenses | |||||
| Accrual of legal fees for the short-term loan | |||||
| Common Stock issued in exchange for crypto assets | |||||
| Convertible notes issued for CSI acquisition | |||||
| Non cash common shares issued in CSI acquisition | |||||
| Issuance of common stock to NYIAX | |||||
| Issuance of warrants with the 2025 Notes | |||||
| Issuance of common stock from non-cash conversion of convertible notes | |||||
| DV Convertible Note | |||||
| CSI Convertible Notes | |||||
| 10% Note conversions | |||||
| Issuance of common stock for waiver shares | |||||
| Common stock issued for intangibles | |||||
Loading...